G

Genmab A/S ADS
D

GMAB

22.340
USD
-0.10
(-0.42%)
مغلق
حجم التداول
58,910
الربح لكل سهم
12
العائد الربحي
-
P/E
13
حجم السوق
14,194,875,989
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    BIIB
    BIIB
    3.560
    (2.60%)
    140.630 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    BNTX
    BNTX
    2.240
    (1.90%)
    120.100 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    ILMN
    ILMN
    -3.080
    (-3.17%)
    94.180 USD
    I
    INCY
    0.790
    (1.11%)
    72.150 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: Genmab A/S ADS

القطاع: Healthcare
الصناعة: Biotechnology
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.